The trials are out there. They are buried. Its up to you to find them.
CAMBRIDGE, Mass. -- October 19, 2010
Zalicus Inc. (NASDAQ: ZLCS) presented data today on its research regarding
novel synergistic drug combinations for the treatment of cancer at the
ASCO-NCI-EORTC Molecular Markers meeting in Hollywood, FL on October 19, 2010.
The poster entitled “Systematic Combination Screening Exploits Tumor Biology
Networks to Create Context-specific Cytotoxicity”, Short, et.al, explores
the association of cancer cell line genotype to combination drug
sensitivity as a predictor of synergy and potentially responsive patient
Dr. Short and the Zalicus research team confirmed that broad synergy
profiling, as opposed to single-agent response data, is required to maximally
exploit drug synergy. Specifically, the team has demonstrated that temporal
sequencing of drug combinations can yield greater synergy and overcome
resistant phenotypes thereby increasing the probability of context-specific
cytotoxicity. Importantly, this work establishes that correlating
chemo-sensitivity and genomic determinants can be leveraged to identify
potentially responsive patient populations.
“These data, which were generated with our combination high-throughput
screening (cHTS™) technology, are in alignment with the goals of our Novartis
oncology collaboration whereby we can begin to associate drug sensitivity to
genotype and in so doing, identify patient populations that may benefit from
any given combination therapy,” commented Mark H.N. Corrigan, M.D., President
and CEO of Zalicus Inc.
Just a few that have recently been updated and are fairly new since the collaboration started. Looks like the Novartis partnership is alive and well. Too many to list here. The list goes on and on......
Just look at clinical trials(dot)gov and you will find a boat load of combination drug trials for cancer and there genotypes. This certainly lines up to what Mr. Corrigan referred to at the ASCO-NCI-EORTC Molecular Markers meeting.
Not yet open to enrollment-
6/2012- A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER
4/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
10/2010- A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
5/2012- A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
9/2011-An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
6/2010-A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
5/2012-A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer
Sentiment: Strong Buy
It all began here. The entire Novartis compound library opened and entered into Zalicus's proprietary ULTRA Combination screening software. It became "Ultra" when the cancer genotypes were added to the assay models. An AMAZING partnership between these two firms.
MARK THIS POST- The lid will blow on this stock when the investment community decides to value this partnership.
Man what a pipeline for combination drug trials, the list goes on an on.....
quite a few have results in the first half of 2013-
10/2012-A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
10/2012-An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer4/2012- Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
5/2011- A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
1/2012- A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
4/2012- A Randomized, Double-blind, Placebo Controlled, Phase II Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation
5/2011- A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations